EQUALY sa.

EQUALY sa.

Slogan: An immuno-oncology discovery-stage biotech company that develops an innovative approach against cancer.

Equaly is a discovery-stage biotechnology company, dedicated to leverage the role of a newly discovered type of Natural Killer T (“NKT”) cells to propose an innovative immunological approach to fight and eliminate tumour cells.

Based on a newly discovered population of NKT lymphocytes, that can be activated by specific antigen through the same mechanism for everyone, allowing allogenic applications, Equaly develops innovative therapies that have the potential to revolutionise the treatment of cancers by offering a safer, more effective, and more affordable option than current therapies.

Using the dynamic of the very same NKT cells, Equaly also develops non-immunogenic versions of existing Enzyme Replacement Therapies against metabolic orphan diseases.

Founded: 2016

Industries: Biotechnology, Health Care

Headquarter: Belgium

Last Investment: N/A

Last Investment Investors: N/A

This discovery-stage biotech startup, EQUALY, focuses on utilizing NKT cells to develop innovative therapies in the fields of cancer treatment and metabolic orphan diseases. Founded in 2016 in Belgium, this company aims to revolutionize cancer treatment by offering safer, more effective, and more affordable options compared to current therapies. Currently, there is no information available regarding the last investment or investors.